



Attorney Docket No.: 6359.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bowler et al.

Serial No.: 10/770,705

Group Art Unit: To Be Assigned

Filed: February 3, 2004

Examiner: To Be Assigned

For: Novel 2, 4-Diaminothiazole Derivatives

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:


1. Information Disclosure Statement
2. Form PTO-1449
3. Copy of References (13)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

on **April 27, 2004**

Gwendolyn Wardell-O'Neal
(name of person mailing paper)


(signature of person mailing paper)



Attorney Docket No.: 6359.204-US

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Bowler et al.

Application No.: 10/770,705

Group Art Unit: To Be Assigned

Filed: February 3, 2004

Examiner: To Be Assigned

For: Novel 2, 4-Diaminothiazole Derivatives

INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

1. US Patent No. 6,214,852 B1
2. WO 98/16528 A1
3. WO 99/21845 A3
4. WO 99/65897 A1


5. WO 00/21927 A3
6. WO 00/38675 A1
7. WO 00/75120 A1
8. WO 01/09106 A1
9. WO 01/44206 A1
10. WO 01/44246 A1
11. WO 01/56567 A1
12. WO 01/74771 A1
13. International Search Report dated November 13, 2002

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,


Date: April 27, 2004


Richard W. Bork, Reg. No. 36,459
Novo Nordisk Pharmaceuticals, Inc.
100 College Road West
Princeton, NJ 08540
(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

FORM PTO-1449
(Rev. 2-82)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6359.204-US

Serial No. 10/770,705

INFORMATION DISCLOSURE
STATEMENT BY APPLICANTApplicant **Bowler et al.**

(Use several sheets if necessary)

Filing Date **February 3, 2004**Group **To Be Assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	6,214,852 B1	4/10/01	Kim et al.	514	369	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	WO 98/16528 A1	4/23/98	PCT				
	WO 99/21845 A3	5/6/99	PCT				
	WO 99/65897 A1	12/23/99	PCT				
	WO 00/21927 A3	4/20/00	PCT				
	WO 00/38675 A1	7/6/00	PCT				
	WO 00/75120 A1	12/14/00	PCT				
	WO 01/09106 A1	2/8/01	PCT				
	WO 01/44206 A1	6/21/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		International Search Renort dated November 13 2002

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 6359.204-US

Serial No. 10/770,705

INFORMATION DISCLOSURE
STATEMENT BY APPLICANT

(Use several sheets if necessary)

Applicant **Bowler et al.**Filing Date **February 3, 2004**Group **To Be Assigned**

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
		WO 01/44246 A1	6/21/01	PCT				
		WO 01/56567 A1	8/9/01	PCT				
		WO 01/74771 A1	10/11/01	PCT				

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.